Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/3/2024 | $82.00 → $100.00 | Buy | BTIG Research |
| 12/3/2024 | $63.00 → $70.00 | Buy | H.C. Wainwright |
| 11/22/2024 | $79.00 | Outperform | Leerink Partners |
| 10/24/2024 | $69.00 | Buy | UBS |
| 9/6/2024 | $70.00 | Buy | Stifel |
| 5/30/2024 | $47.00 | Sector Perform | Scotiabank |
| 3/21/2024 | $62.00 | Buy | BTIG Research |
| 3/20/2024 | $100.00 | Overweight | Cantor Fitzgerald |
8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
424B5 - Janux Therapeutics, Inc. (0001817713) (Filer)
424B5 - Janux Therapeutics, Inc. (0001817713) (Filer)
BTIG Research reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $100.00 from $82.00 previously
H.C. Wainwright reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $70.00 from $63.00 previously
Leerink Partners initiated coverage of Janux Therapeutics with a rating of Outperform and set a new price target of $79.00
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street's leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the closing of its previously announced underwritten public offering of 6,150,793 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 833,333 additional shares of common stock, at a public offering price of $63.00 per share and pre-funded warrants to purchase 238,095 shares of common stock at a price of $62.999 per pre-funded war
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the pricing of an underwritten public offering of 5,317,460 shares of its common stock at a public offering price of $63.00 per share and pre-funded warrants to purchase 238,095 shares of common stock at a price of $62.999 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gro
Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica
The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board member Ronald W. Barrett, Ph.D., as Chairperson Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer. "The appointment of Tommy to CSO is another important milestone for our company. Tommy was essential in our initial efforts to discover and engineer a tumor-activated technology for solid tumors and has since played a critical role in optimizing the applications for our TRACTr and TRACIr platforms while supporting our clinical
Presented positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer Management team bolstered with key appointment $303.3 million in cash, cash equivalents, and short-term investments at end of second quarter 2023 In July, further strengthened balance sheet with approximately $60 million offering Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the second quarter ended June 30, 2
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)